Piper Jaffray analyst Joshua Schimmer said Gilead's GS-0976 program in the treatment of NASH are the company's "most interesting" and the just announced data for the ACC inhibitor in a 10 patient study are very encouraging. The analyst, who continues to believe that reducing lipids is a key component for treating NASH, added that long term safety for inhibition of ACC will be necessary before he can have confidence in the program's potential. He keeps an Overweight rating on Gilead shares.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Consensus $3.67. Sees FY24 product sales $27.1B-$27.5B.

Reports Q1 revenue $6.7B, consensus $5.92B. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a regulatory decision on seladelpar is expected in August. New HIV data demonstrates the continued progress in our long-acting HIV pipeline, and we look forward to providing updates on this and our broad Oncology portfolio throughout the rest of 2024."